Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine for Cognitive Improvement in MDD (VENUS)
NCT05104918Phase 3Unknown
- Sponsor
- Scotmann Pharmaceuticals
- Start
- Feb 2022
- Primary completion
- Apr 2022
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of vortioxetine in major depressive disorder (MDD), sponsored by Scotmann Pharmaceuticals. Status: unknown.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05104918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05104918.